VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Nov 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-11-15

Reporting Person: Arbuckle Stuart A (EVP, COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-15	Common Stock	S	2	$186.99	Disposed	41104	Direct
2021-11-15	Common Stock	S	1	$187.80	Disposed	41103	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $186.99 (range $186.67 to $187.31).

F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.